A national study of medical care expenditures for musculoskeletal conditions: The impact of health insurance and managed care

Arthritis and Rheumatism

Volumn 44, Issue 5, 2001, Pages 1160-1169

  Yelin, Edward ^a,b   Herrndorf, Aldona ^a   Trupin, Laura ^a   Sonneborn, Dean ^a  

^a Arthritis Research Group   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HEALTH CARE COST; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MANAGED CARE; MUSCULOSKELETAL DISEASE; PRESCRIPTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; UNITED STATES;

ADOLESCENT; ADULT; AMBULATORY CARE; COST OF ILLNESS; HEALTH EXPENDITURES; HEALTH MAINTENANCE ORGANIZATIONS; HOME CARE AGENCIES; HOSPITALIZATION; HUMANS; INSURANCE, HEALTH; MANAGED CARE PROGRAMS; MIDDLE AGED; MUSCULOSKELETAL DISEASES; UNITED STATES;

EID: 0035025988     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200105)44:5<1160::AID-ANR199>3.0.CO;2-Y     Document Type: Article

References (48)

1. Rice D. The economic burden of musculoskeletal conditions, U.S., 1995. In: Praemer A, Furner S, Rice D, editors. Musculoskeletal conditions in the U.S. Rosemont (IL): American Academy of Orthopedic Surgeons; 1999.
2. Rice D. Estimating the cost of illness. Hyattsville (MD): National Center for Health Statistics; 1966. Health Economics Series, No.: 6.
3. Cooper B, Rice D. The economic cost of illness revisited. Soc Secur Bull 1979;39:21-35.
4. Rice D, Hodgson T, Kopstein A. The economic costs of illness: a replication and update. Health Care Financ Rev 1985;7:61-80.
5. Wigle D, Mao Y, Wong T, Lane R. Economic burden of illness in Canada. 1986. Chronic Dis Can 1991;12:1-12.
6. Badley E. The economic burden of musculoskeletal disorders in Canada is similar to that for cancer, and may be higher. J Rheumatol 1995;22:204-6.
7. Yelin E, Callahan LF, for the National Arthritis Data Work Group. The economic cost and social and psychological impact of musculoskeletal conditions. Arthritis Rheum 1995;38:1351-62.
8. Meenan RF, Yelin EH, Henke CJ, Curtis DL, Epstein WV. The costs of rheumatoid arthritis: a patient-oriented study of chronic disease costs. Arthritis Rheum 1978;21:827-33.
9. Stone C. The lifetime economic costs of rheumatoid arthritis. J Rheumatol 1984;11:818-27.
10. Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell DM, Roth SH. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986;29:488-93.
11. Jacobs J, Keyserling JA, Britton M, Morgan GJ Jr, Wilkenfeld J, Hutchings HC. The total cost of care and the use of pharmaceuticals in the management of rheumatoid arthritis: the Medi-Cal program. J Clin Epidemiol 1988;41:215-33.
12. Jonsson B, Rehnberg C, Borgquist L, Larsson SE. Locomotion status and costs in destructive rheumatoid arthritis. Acta Orthop Scand 1992;63:207-12.
13. Eberhardt K, Larsson B, Nived K. Early rheumatoid arthritis-some social, economical, and psychological aspects. Scand J Rheumatol 1993;22:119-23.
14. Allaire S, Prashker M, Meenan R. The cost of rheumatoid arthritis. Pharmacoeconomics 1994;6:513-22.
15. Prashker MJ, Meenan RF. The total costs of drug therapy for rheumatoid arthritis: a model based on costs of drug, monitoring, and toxicity. Arthritis Rheum 1995;38:318-25.
16. MacLean CH, Knight KK, Shekelle PG, Paulus HE, Brook RH. Costs attributable to arthritis implications of costs [abstract]. Arthritis Rheum 1996;39 Suppl 9:S317.
17. Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol Suppl 1996;44:47-51.
18. Lanes SF, Lanza LL, Radensky PW, Yood RA, Meenan RF, Walker AM, et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthritis Rheum 1997;40:1475-81.
19. Clarke AE, Zowall H, Levinton C, Assimakopoulos H, Sibley JT, Haga M, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 1997;24:1051-60.
20. Sangha O, Stucki G. Economic impact of rheumatologic disorders. Curr Opin Rheumatol 1997;9:102-5.
21. Van Jaarsveld CH, Jacobs JW, Schrijvers AJ, Heurkens AH, Haanen HC, Bijlsma JW. Direct cost of rheumatoid arthritis during the first six years: a cost of illness study. Br J Rheumatol 1998;37:837-47.
22. Clarke AE, Levinton C, Joseph L, Penrod J, Zowall H, Sibley JT, et al. Predicting the short-term direct medical cosls incurred by patients with rheumatoid arthritis. J Rheumatol 1999;26:1068-75.
23. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999;42:1209-18.
24. Liang MH, Larson M, Thompson M, Eaton H, McNamara E, Katz R, et al. Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1984;27:522-9.
25. Thompson M, Read J, Liang M. Feasibility of willingness to pay measurements in chronic arthritis. Med Decis Making 1984;4: 195-212.
26. Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Direct medical costs unique to people with arthritis. J Rheumatol 1996; 24:719-25.
27. Rothfuss J, Mau W, Zeidler H, Brenner MH. Socioeconomic evaluation of rheumatoid arthritis and osteoarthritis: a literature review. Semin Arthritis Rheum 1997;26:771-9.
28. Allaire SH, DeNardo BS, Szer IS, Meenan RF, Schaller JG. The economic impacts of juvenile rheumatoid arthritis. J Rheumatol 1992;19:952-5.
29. Lubeck D, Brown B, Holman H. Chronic disease and health system performance: care of osteoarthritis across three health services. Med Care 1985;23:266-77.
30. Gabriel SE, Crowson CS, O'Fallon WM. Costs of osteoarthritis: estimates from a geographically defined population. J Rheumatol Suppl 1995;43:23-5.
31. Yelin E. The economic impact of osteoarthritis. In: Baker J, Brandt K, editors. Reappraisal of the management of patients with osteoarthritis. Springfield (NJ): Scientific Therapeutics Information; 1993:9-13.
32. Clarke AE, Esdaile JM, Bloch DA, Lacaille D, Danoff DS, Fries JF. A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs. Arthritis Rheum 1993;36:1548-59.
33. LaCaille D, Clarke AE, Bloch DA, Danoff DS, Fries JF. The impact of disease activity, treatment, and disease severity on short term costs of systemic lupus crythematosus. J Rheumatol 1994;21: 448-53.
34. Gironimi G, Clarke AE, Hamilton VH, Danoff DS, Bloch DA, Fries JF, et al. Why health care costs more in the US: comparing health care expenditures between systemic lupus erythematosus patients in Stanford and Montreal. Arthritis Rheum 1996;39: 979-87.
35. Webster B, Snook S. The cost of compensable low back pain. J Occup Med 1990;32:13-5.
36. Manning F, Barondess J, editors. Changing health care systems and rheumatic disease. Washington: National Academy Press; 1996.
37. Yelin EH, Henke CJ, Kramer JS, Nevitt MC, Shearn M, Epstein WV. A comparison of the treatment of rheumatoid arthritis in health maintenance organizations and fee-for-service practices. N Engl J Med 1985;312:962-7.
38. Yelin EH, Criswell LA, Feigenbaum PG. Health care utilization and outcomes among persons with rheumatoid arthritis in fee-for-service and pre-paid group practices. JAMA 1996;276:1048-53.
39. Lubeck D, Brown B, Holman H. Chronic disease and health system performance: care of osteoarthritis across three health services. Med Care 1985;23:266-77.
40. Feinglass J, Schroeder JL, Gifford B, Manheim LM. Gatekeepers and the medical specialist: the impact of managed care on rheumatologists. AAPPO J 1992;2:13-36.
41. Cohen S. Sample design of the 1996 Medical Expenditure Panel Survey Household Component. Rockville (MD): Agency for Health Care Policy and Research: 1997. MEPS Methodology Report No.: 2. AHCPR Publication No.: 97-0027.
42. Agency for Healthcare Research and Quality. MEPS Household Component 1996 full year use and expenditure data: public use documentation. Rockville (MD): Agency for Healthcare Research and Quality, 1999, C6-C11.
43. Hoffman C, Rice D, Sung H. Persons with chronic conditions: their prevalence and costs. JAMA 1996;276:1473-9.
44. Cohen S, DiGaetano R, Goksel H. Estimation procedures in the 1996 Medical Expenditure Panel Survey Household Component. Rockville (MD): Agency for Health Care Policy and Research; 1999. MEPS Methodology Report No.: 5. AHCPR Publication No.: 99-0027.
45. Shah B, Barnwell B, Bieler G. SUDAAN: Software for the statistical analysis of correlated data. User's manual, release 7.0. Research Triangle Park (NC): Research Triangle Institute; 1996.
46. National Institute on Drug Abuse. The economic costs of alcohol and drug abuse in the United States, 1992. NIH Publication No. 48-4327. September 1998, Appendix B.
47. Duan N, Manning WG, Morris CN, Newhouse JP. A comparison of alternative models for the demand for medical care. J Business Econ Statistics 1983;1:115-26.
48. U.S. Bureau of the Census. Statistical abstract of the United States, Pittsburgh: GPO; 1998.